Therapeutic area intelligence for BTK Inhibitor with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 1

Companies

Roche →

Assets

fenebrutinib →

Janssen →

Recent signals(2)

ClinicalJuly 19, 2026

Long-term safety and efficacy study of ibrutinib initiated by Janssen

A long-term extension study for ibrutinib has been initiated to gather ongoing safety and efficacy data.

StrategyJune 17, 2026

Roche Reports Strong Q1 2026 Sales Growth Driven by Innovative Medicines and Diagnostics

Roche's Q1 2026 sales grew 6% at constant exchange rates, driven by strong demand for innovative medicines, particularly in multiple sclerosis and oncology.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.